Acute

Vincerx Pharma Presents Preclinical Data on VIP943 in Models of Acute Myeloid Leukemia at the 2022 American Society of Hematology 64th Annual Meeting.

Vincerx’s proprietary carrier and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significantly improved safety in non-human primates (NHPs) compared to Mylotarg™ (gemtuzumab ozogamicin). VIP943 demonstrated monotherapy activity in ex vivo AML models and in vivo activity with significant tumor regression in combination with venetoclax and azacitidine …

Vincerx Pharma Presents Preclinical Data on VIP943 in Models of Acute Myeloid Leukemia at the 2022 American Society of Hematology 64th Annual Meeting. Read More »

Kymera Therapeutics Presents Preclinical Data Showing Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in AML xenograft models KT-253 showed combinatorial benefit with the BCL-2 inhibitor venetoclax in a model of venetoclax-resistant AML KT-253 is also active in other hematologic malignancies including DLBCL WATERTOWN, Massachusetts, Dec. 11, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, …

Kymera Therapeutics Presents Preclinical Data Showing Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting Read More »